Company Overview and News
ShareRoot Ltd (ASX:SRO) continues to advance its MediaConsent platform, a solution for companies aiming to be compliant with data privacy regulations such as the GDPR.
ShareRoot Ltd (ASX:SRO) has appointed Antanas ‘Tony’ Guoga, better known as Tony G, to its advisory board.
ShareRoot Ltd (ASX:SRO) has received an ASX price and volume query after its shares increased to 0.8 cents from 0.6 cents on above-average volume yesterday.
ShareRoot (ASX:SRO) CEO Noah Abelson-Gertler speaks to Proactive Investors about the company's recent advancements, set against the backdrop of the European Union’s General Data Protection Regulation (GDPR) being enacted.
ShareRoot Ltd (ASX:SRO) is closing the current financial year in a confident position as its platform and service assets are expected to drive a stronger 2018/19 financial year.
ShareRoot (ASX:SRO) CEO Noah Abelson-Gertler explains how recent changes to the board represent a key transition towards profitability for the company’s User Generated Content (UGC) Legal Rights Management platform.
ShareRoot Ltd (ASX:SRO) will be shifting into profitability after the completion of new features for its user-generated content (UGC) legal rights platform.
ShareRoot (ASX:SRO) CEO Noah Abelson-Gertler tells Proactive Investors the company has appointed Paul-Olivier Dehaye, a data and privacy expert, to join the advisory board.
ShareRoot Ltd (ASX:SRO) has appointed Dr Paul-Olivier Dehaye and Jerome Groetenbriel, both co-founders of PersonalData.IO, experts in customer data collection, mining and protection as advisors to the company.
ShareRoot Ltd (ASX:SRO) has completed the acquisition of The Social Science (TSS), expanding the company’s product offering.
Noah Abelson-Gertler, chief executive of ShareRoot Ltd (ASX:SRO), updates Proactive Investors ahead of presentations at the TechKnow Invest Roadshow in Sydney on April 10 and Melbourne on April 12.
ShareRoot Limited (ASX:SRO) has strengthened its sales pipeline after securing four contract renewals, one of which is a high profile global retail chain.
COST SRO MCD
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to ASX:SRO / SHAREROOT LTD on message board site Silicon Investor.